EU No-Deal Scenario Looms Still, But MHRA’s Reg Oversight Of UK Medtech On Hold
Executive Summary
UK parliament’s indecision over how – or if – to enact Brexit saw the planned March 29 withdrawal deadline come and go. The default positions of the inter-ministerial Office for Lifesciences (OLS) and health-care products regulator (MHRA) are still to prepare for a no-deal exit from the EU.
You may also be interested in...
EU Regulatory Roundup, April 2019: Progress Toward Regulation Implementation Steps Up
April 2019 was seemingly a bumper month in terms of the amount of progress toward implementation of the EU Medical Device and IVD Regulations. There is now, finally, a sense that the sector is moving towards implementation of the MDR. But with so much left until so late, will enough progress be achieved in the time left?
The New Culture Club: UK NHS Goes Upstream For Care Delivery And Offers New Chances For Medtechs
Hopes are high for the NHS Long Term Plan’s ability to transform health-care delivery and make a potentially unsustainable service fit for the future. There are opportunities for diagnostics, devices and digital providers, but are the resources there to turn the Plan into a success story?
EU No-Deal Still Haunts UK Medtechs As Brexit Remains On A Knife Edge
The UK is the middle of a week of Brexit votes in Parliament, but confusion for medtechs and the wider industrial community has not been quelled at all, regardless of two days of voting already, and a third to come today.